recent publications

• academic article

  • Zeng, Y., Huebener, N., Fest, S., Weixler, S., Schroeder, U., Gaedicke, G., Xiang, R., Schramm, A., Eggert, A., Reisfeld, R. A., Lode, H. N. Fractalkine (cx3cl1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by t cells and natural killer cells Cancer Research  2007 67:2331-2338  DOI:10.1158/0008-5472.can-06-3041  PMID:17332365
  • Zeng, Y., Jiang, J., Huebener, N., Wenkel, J., Gaedicke, G., Xiang, R., Lode, H. N. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted il-2 Cancer Letters  2005 228:187-193  DOI:10.1016/j.canlet.2005.01.057  PMID:15953676
  • Niethammer, A. G., Wodrich, H., Loeffler, M., Lode, H. N., Emmerich, K., Abdollahi, A., Krempien, R., Debus, J., Huber, P. E., Reisfeld, R. A. Multidrug resistance-1 (mdr-1): A new target for t cell-based immunotherapy FASEB Journal  2005 19:158-159  DOI:10.1096/fj.04-2355fje  PMID:15498893
  • Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Enhanced activity of hu14.18-il2 immunocytokine against murine nxs2 neuroblastoma when combined with interleukin 2 therapy Clinical Cancer Research  2004 10:4839-4847  DOI:10.1158/1078-0432.ccr-03-0799  PMID:15269160
  • Neal, Z. C., Imboden, M., Rakhmilevich, A. L., Kim, K. M., Hank, J. A., Surfus, J., Dixon, J. R., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Nxs2 murine neuroblastomas express increased levels of mhc class i antigens upon recurrence following nk-dependent immunotherapy Cancer Immunology Immunotherapy  2004 53:41-52  DOI:10.1007/s00262-003-0435-2  PMID:14504825
  • Schroeder, U., Bernt, K. M., Lange, B., Wenkel, J., Jikai, J., Shabat, D., Amir, R., Huebener, N., Niethammer, A. G., Hagemeier, C., Wiebusch, L., Gaedicke, G., et al. Hydrolytically activated etoposide prodrugs inhibit mdr-1 function and eradicate established mr-1 multidrug-resistant t-cell leukemia Blood  2003 102:246-253  DOI:10.1182/blood-2002-07-2268  PMID:12623853
  • Pertl, U., Wodrich, H., Ruehlmann, J. M., Gillies, S. D., Lode, H. N., Reisfeld, R. A. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood  2003 101:649-654  DOI:10.1182/blood-2002-02-0391  PMID:12393580
  • Wrasidlo, W., Gaedicke, G., Guy, R. K., Renaud, J., Pitsinos, E., Nicolaou, K. C., Reisfeld, R. A., Lode, H. N. A novel 2 '-(n-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models Bioconjugate Chemistry  2002 13:1093-1099  DOI:10.1021/bc0200226  PMID:12236791
  • Xiang, R., Primus, F. J., Ruehlmann, J. M., Niethammer, A. G., Silletti, S., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. A dual-function DNA vaccine encoding carcinoembryonic antigen and cd40 ligand trimer induces t cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice Journal of Immunology  2001 167:4560-4565  PMID:11591784
  • Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., Lode, H. N. Ifn-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific cd8 t cell response induced by single-chain il-12 gene therapy Journal of Immunology  2001 166:6944-6951  PMID:11359856
  • Shabat, D., Lode, H. N., Pertl, U., Reisfeld, R. A., Rader, C., Lerner, R. A., Barbas, C. F. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy Proceedings of the National Academy of Sciences of the United States of America  2001 98:7528-7533  DOI:10.1073/pnas.131187998  PMID:11404472  PMCID:PMC34702
  • Xiang, R., Silletti, S., Lode, H. N., Dolman, C. S., Ruehlmann, J. M., Niethammer, A. G., Pertl, U., Gillies, S. D., Primus, F. J., Reisfeld, R. A. Protective immunity against human carcinoembryonic antigen (cea) induced by an oral DNA vaccine in cea-transgenic mice Clinical Cancer Research  2001 7:856S-864S  PMID:11300483
  • Niethammer, A. G., Xiang, R., Ruehlmann, J. M., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma Cancer Research  2001 61:6178-6184  PMID:11507070
  • Xiang, R., Lode, H. N., Chao, T. H., Ruehlmann, J. M., Dolman, C. S., Rodriguez, F., Whitton, J. L., Overwijk, W. W., Restifo, N. P., Reisfeld, R. A. An autologous oral DNA vaccine protects against murine melanoma Proceedings of the National Academy of Sciences of the United States of America  2000 97:5492-5497  DOI:10.1073/pnas.090097697  PMID:10779556  PMCID:PMC25856
  • Balicki, D., Reisfeld, R. A., Pertl, U., Beutler, E., Lode, H. N. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America  2000 97:11500-11504  DOI:10.1073/pnas.210382997  PMID:11016973  PMCID:PMC17229
  • Lode, H. N., Xiang, R., Pertl, U., Forster, E., Schoenberger, S. P., Gillies, S. D., Reisfeld, R. A. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction Journal of Clinical Investigation  2000 105:1623-1630  DOI:10.1172/jci9177  PMID:10841521  PMCID:PMC300854
  • Lode, H. N., Reisfeld, R. A. Targeted cytokines for cancer immunotherapy Immunologic Research  2000 21:279-288  DOI:10.1385/ir:21:2-3:279  PMID:10852128
  • Lode, H. N., Pertl, U., Xiang, R., Gaedicke, G., Reisfeld, R. A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma Medical and Pediatric Oncology  2000 35:641-646  DOI:10.1002/1096-911x(20001201)35:6<641::aid-mpo34>3.0.co;2-r  PMID:11107137
  • Lode, H. N., Xiang, R., Perri, P., Pertl, U., Lode, A., Gillies, S. D., Reisfeld, R. A. What to do with targeted il-2 Drugs of Today  2000 36:321-336  PMID:12861355
  • Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., Reisfeld, R. A. Synergy between an antiangiogenic integrin alpha(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proceedings of the National Academy of Sciences of the United States of America  1999 96:1591-1596  DOI:10.1073/pnas.96.4.1591  PMID:9990069
  • Xiang, R., Lode, H. N., Gillies, S. D., Reisfeld, R. A. T cell memory against colon carcinoma is long-lived absence of antigen Journal of Immunology  1999 163:3676-3683  PMID:10490962
  • Lode, H. N., Xiang, R., Duncan, S. R., Theofilopoulos, A. N., Gillies, S. D., Reisfeld, R. A. Tumor-targeted il-2 amplifies t cell-mediated immune response induced by gene therapy with single-chain il-12 Proceedings of the National Academy of Sciences of the United States of America  1999 96:8591-8596  DOI:10.1073/pnas.96.15.8591  PMID:10411920
  • Lode, H. N., Dreier, T., Xiang, R., Varki, N. M., Kang, A. S., Reisfeld, R. A. Gene therapy with a single chain interleukin 12 fusion protein induces t cell-dependent protective immunity in a syngeneic model of murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America  1998 95:2475-2480  DOI:10.1073/pnas.95.5.2475  PMID:9482910
  • Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., Reisfeld, R. A. Immunocytokines: A promising approach to cancer immunotherapy Pharmacology & Therapeutics  1998 80:277-292  DOI:10.1016/s0163-7258(98)00033-3  PMID:9888698
  • Xiang, R., Lode, H. N., Dreier, T., Gillies, S. D., Reisfeld, R. A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases Cancer Research  1998 58:3918-3925  PMID:9731503
  • Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., Reisfeld, R. A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood  1998 91:1706-1715  PMID:9473237
  • Dreier, T., Lode, H. N., Xiang, R., Dolman, C. S., Reisfeld, R. A., Kang, A. S. Recombinant immunocytokines targeting the mouse transferrin receptor: Construction and biological activities Bioconjugate Chemistry  1998 9:482-489  DOI:10.1021/bc980020e  PMID:9667950
  • Dolman, C. S., Mueller, B. M., Lode, H. N., Xiang, R., Gillies, S. D., Reisfeld, R. A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clinical Cancer Research  1998 4:2551-2557  PMID:9796990
  • Lode, H. N., Reisfeld, R. A., Handgretinger, R., Nicolaou, K. C., Gaedicke, G., Wrasidlo, W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(i)(1) effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma Cancer Research  1998 58:2925-2928  PMID:9679947
  • Pertl, U., Xiang, R., Kleindienst, P., Becker, J. C., Gillies, S. D., Reisfeld, R. A., Lode, H. N. Tumor targeting with immunocytokines. A novel approach for cancer therapy Minerva Biotecnologica  1998 10:89-99
  • Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X. Q., Lo, K. M., Lan, Y., Super, M., Gillies, S. D., Reisfeld, R. A. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Research  1997 57:4948-4955  PMID:9354462
  • Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow Journal of the National Cancer Institute  1997 89:1586-1594  DOI:10.1093/jnci/89.21.1586  PMID:9362156